Once-weekly semaglutide significantly improved liver histology in patients with MASH and fibrosis, compared to placebo. It also achieved substantial weight loss, although gastrointestinal side effects were more common. Semaglutide improved noninvasive liver markers, though the high placebo response underscores the need for more precise monitoring tools.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?